These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 1396108)

  • 1. Buprenorphine alone and in combination with naloxone in non-dependent humans.
    Weinhold LL; Preston KL; Farre M; Liebson IA; Bigelow GE
    Drug Alcohol Depend; 1992 Aug; 30(3):263-74. PubMed ID: 1396108
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intranasal buprenorphine alone and in combination with naloxone: Abuse liability and reinforcing efficacy in physically dependent opioid abusers.
    Walsh SL; Nuzzo PA; Babalonis S; Casselton V; Lofwall MR
    Drug Alcohol Depend; 2016 May; 162():190-8. PubMed ID: 27012435
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acute effects of buprenorphine, hydromorphone and naloxone in methadone-maintained volunteers.
    Strain EC; Preston KL; Liebson IA; Bigelow GE
    J Pharmacol Exp Ther; 1992 Jun; 261(3):985-93. PubMed ID: 1376362
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acute effects of intramuscular and sublingual buprenorphine and buprenorphine/naloxone in non-dependent opioid abusers.
    Duke AN; Correia CJ; Walsh SL; Bigelow GE; Strain EC
    Psychopharmacology (Berl); 2010 Aug; 211(3):303-12. PubMed ID: 20577717
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Buprenorphine and naloxone alone and in combination in opioid-dependent humans.
    Preston KL; Bigelow GE; Liebson IA
    Psychopharmacology (Berl); 1988; 94(4):484-90. PubMed ID: 2453895
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of buprenorphine/naloxone in opioid-dependent humans.
    Stoller KB; Bigelow GE; Walsh SL; Strain EC
    Psychopharmacology (Berl); 2001 Mar; 154(3):230-42. PubMed ID: 11351930
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical and pharmacological evaluation of buprenorphine and naloxone combinations: why the 4:1 ratio for treatment?
    Mendelson J; Jones RT
    Drug Alcohol Depend; 2003 May; 70(2 Suppl):S29-37. PubMed ID: 12738348
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Self-administration of intravenous buprenorphine and the buprenorphine/naloxone combination by recently detoxified heroin abusers.
    Comer SD; Collins ED
    J Pharmacol Exp Ther; 2002 Nov; 303(2):695-703. PubMed ID: 12388653
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of buprenorphine versus buprenorphine/naloxone tablets in non-dependent opioid abusers.
    Strain EC; Stoller K; Walsh SL; Bigelow GE
    Psychopharmacology (Berl); 2000 Mar; 148(4):374-83. PubMed ID: 10928310
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Buprenorphine's physical dependence potential: antagonist-precipitated withdrawal in humans.
    Eissenberg T; Greenwald MK; Johnson RE; Liebson IA; Bigelow GE; Stitzer ML
    J Pharmacol Exp Ther; 1996 Feb; 276(2):449-59. PubMed ID: 8632309
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Buprenorphine effects in methadone-maintained volunteers: effects at two hours after methadone.
    Strain EC; Preston KL; Liebson IA; Bigelow GE
    J Pharmacol Exp Ther; 1995 Feb; 272(2):628-38. PubMed ID: 7853176
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Blockade of hydromorphone effects by buprenorphine/naloxone and buprenorphine.
    Strain EC; Walsh SL; Bigelow GE
    Psychopharmacology (Berl); 2002 Jan; 159(2):161-6. PubMed ID: 11862344
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhanced buprenorphine analgesia with the addition of ultra-low-dose naloxone in healthy subjects.
    La Vincente SF; White JM; Somogyi AA; Bochner F; Chapleo CB
    Clin Pharmacol Ther; 2008 Jan; 83(1):144-52. PubMed ID: 17568402
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics and subjective effects of sublingual buprenorphine, alone or in combination with naloxone: lack of dose proportionality.
    Harris DS; Mendelson JE; Lin ET; Upton RA; Jones RT
    Clin Pharmacokinet; 2004; 43(5):329-40. PubMed ID: 15080765
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Buprenorphine and naloxone interactions in methadone maintenance patients.
    Mendelson J; Jones RT; Welm S; Brown J; Batki SL
    Biol Psychiatry; 1997 Jun; 41(11):1095-101. PubMed ID: 9146820
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Buprenorphine, morphine and naloxone effects during ascending morphine maintenance in humans.
    Schuh KJ; Walsh SL; Bigelow GE; Preston KL; Stitzer ML
    J Pharmacol Exp Ther; 1996 Aug; 278(2):836-46. PubMed ID: 8768738
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and efficacy of buprenorphine/naloxone in opioid-dependent patients: an Italian observational study.
    Magnelli F; Biondi L; Calabria R; Fiore A; Peluso E; Vonella D; Rota AG
    Clin Drug Investig; 2010; 30 Suppl 1():21-6. PubMed ID: 20450242
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic switch to buprenorphine/naloxone from buprenorphine alone: clinical experience in an Italian addiction centre.
    Montesano F; Zaccone D; Battaglia E; Genco F; Mellace V
    Clin Drug Investig; 2010; 30 Suppl 1():13-9. PubMed ID: 20450241
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rewarding or aversive effects of buprenorphine/naloxone combination (Suboxone) depend on conditioning trial duration.
    Canestrelli C; Marie N; Noble F
    Int J Neuropsychopharmacol; 2014 Sep; 17(9):1367-73. PubMed ID: 24606726
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Naloxone reversal of opioid-induced respiratory depression with special emphasis on the partial agonist/antagonist buprenorphine.
    Sarton E; Teppema L; Dahan A
    Adv Exp Med Biol; 2008; 605():486-91. PubMed ID: 18085322
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.